2Seventy Bio (TSVT) Stock Price

2Seventy Bio Price

NASDAQ·CLOSED
5.00
​
Market closed

Revenue at 2Seventy Bio has contracted by 5.9% per year over the past 6 years to 37.86 M USD. For 2Seventy Bio, the net margin of -151.2% is down versus -55.7% a few years ago. The consensus 12-month price target for 2Seventy Bio is 5.10 USD, about 2.0% above where the stock trades today. Of 8 analysts, 0 rate the stock a buy — an overall Hold consensus.

2Seventy Bio stock price

Access this data via the Eulerpool API

2Seventy Bio business model & stock analysis

2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 425 full-time employees. The company went IPO on 2021-10-18. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The Company’s advancing multiple clinical programs, including SC-DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia (AML), and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, or B-NHL, as well as multiple preclinical programs, including bbT4015, an engineered CAR T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb, the Company is delivering Abecma to multiple myeloma patients in the United States.

Frequently asked questions about 2Seventy Bio

Analysts currently set an average price target of 5.10 USD for the 2Seventy Bio stock (median: 5.10 USD), implying +2.0 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the 2Seventy Bio stock: 0 recommend buying, 5 holding and 3 selling. For 2026, analysts expect 2Seventy Bio to generate revenue of 75.12 M USD and earnings per share of -0.15 USD.

Converted at the current exchange rate, the 2Seventy Bio share trades at 4.46 EUR (5.00 USD).

The 2Seventy Bio share (TSVT) is listed on 1 stock exchanges, including: NASDAQ (TSVT).

The expected revenue of 2Seventy Bio is 75.12 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of 2Seventy Bio is -7.85 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of 2Seventy Bio is currently -33.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the 2Seventy Bio stock.

The price-to-sales ratio (P/S) of 2Seventy Bio is currently 3.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the 2Seventy Bio stock.

The Eulerpool Quality Score for 2Seventy Bio is 2/10.

The ISIN of 2Seventy Bio is US9013841070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of 2Seventy Bio is TSVT. The ticker symbol is used to trade 2Seventy Bio shares on the stock exchange.

Fair ValueTerminal
5.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
44,334.89 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 18, 2021
ISIN
US9013841070
Cusip
901384107
Market capitalization
266.15 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-12.29
P/Ee 2026
-33.33
P/Ee 2027
27.78
P/Ee 2028
19.61
P/Ee 2029
17.24
P/S
P/Se
3.82
EV/EBIT
—
P/B Ratio
1.26
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-27.16 %
Last updated Oct 10, 2026, 2:04 AM

2Seventy Bio Peer Group

2Seventy Bio Ticker

NASDAQ · TSVT

2Seventy Bio FIGI

TSVT:US · BBG00YV1J622TSVT:UA · BBG01315V7T8TSVT:UC · BBG01315V7V5TSVT:UN · BBG01315V7X3TSVT:UP · BBG01315V7Y2TSVT:UB · BBG01315V807TSVT:UM · BBG01315V825TSVT:UX · BBG01315V843TSVT:UD · BBG01315V8B5TSVT:UW · BBG01315V8D3TSVT:UF · BBG01315V8F1TSVT:VY · BBG01315V8G0

All fundamentals and in-depth analysis of 2Seventy Bio

Our stock analysis for 2Seventy Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 2Seventy Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.